Improving Patient Care with Novel Blood Cancer Treatments
The Advanced Leukemia Therapies and Research Center at Cincinnati Children’s is home to world-class scientists with a shared goal: to improve outcomes among people with myeloid malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Founded in 2023, the center brings together numerous experts who study blood cancers in children and adults. Our goal is to accelerate the process through which scientific discoveries become lifesaving new therapies.
Facilitating Transformative Research
At the Advanced Leukemia Therapies and Research Center, we support and lead basic science and translational research. At any given time, dozens of our researchers are conducting studies to better understand how MDS and AML develop—and use that knowledge to create novel treatments.
Together, we’re taking new information and insights to the next level (and closer to the clinic) by asking:
- How can we exploit these findings therapeutically?
- Can these discoveries help us determine whether patients will respond to certain treatments?
- Could these findings help us predict which combination of therapies will be most effective?
Learn more about our research initiatives.
Collaboration Leads to Innovation
Not only does our center consolidate all the leukemia research taking place at Cincinnati Children’s, but it also integrates the clinical team. This model benefits scientists, physicians and patients alike because:
- Our researchers have access to biospecimens from patients across the continuum of care. This includes the newly diagnosed, those in remission and those with refractory or recurrent myeloid malignancies (MDS and/or AML).
- Our oncologists can provide feedback about treatment successes and challenges directly to the research team.
- Our patients have access to clinical trials for emerging therapies.
